Azenta, Inc. (NASDAQ:AZTA) Shares Sold by Amalgamated Bank

Amalgamated Bank reduced its position in Azenta, Inc. (NASDAQ:AZTA) by 16.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,846 shares of the company’s stock after selling 4,458 shares during the quarter. Amalgamated Bank’s holdings in Azenta were worth $1,107,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Hantz Financial Services Inc. acquired a new stake in Azenta during the 2nd quarter worth $30,000. Farther Finance Advisors LLC grew its holdings in shares of Azenta by 20.0% during the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock worth $74,000 after buying an additional 256 shares during the last quarter. Benjamin F. Edwards & Company Inc. increased its position in Azenta by 150.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock valued at $84,000 after acquiring an additional 955 shares during the period. Lazard Asset Management LLC acquired a new position in Azenta in the 1st quarter valued at about $130,000. Finally, Acadian Asset Management LLC raised its stake in Azenta by 24.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock valued at $143,000 after acquiring an additional 471 shares during the last quarter. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AZTA. Evercore ISI lowered their target price on Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Needham & Company LLC dropped their price objective on shares of Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Azenta currently has a consensus rating of “Hold” and a consensus target price of $63.60.

Azenta Trading Down 3.2 %

NASDAQ AZTA opened at $44.51 on Thursday. The business’s 50 day moving average is $45.78 and its two-hundred day moving average is $50.59. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of -14.99 and a beta of 1.48. Azenta, Inc. has a 12-month low of $40.24 and a 12-month high of $69.16.

Azenta (NASDAQ:AZTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.07. Azenta had a positive return on equity of 0.98% and a negative net margin of 25.01%. The firm had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $169.66 million. During the same quarter in the prior year, the business posted $0.13 earnings per share. Azenta’s revenue was down 1.2% compared to the same quarter last year. Equities analysts forecast that Azenta, Inc. will post 0.42 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Herman Cueto sold 1,595 shares of the business’s stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $43.68, for a total transaction of $69,669.60. Following the sale, the chief financial officer now owns 24,604 shares of the company’s stock, valued at approximately $1,074,702.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 1.77% of the company’s stock.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.